Lamivudine therapy in HBsAg-carrying breast cancer patients undergoing chemotherapy: prophylactic or preemptive?
Dai
Ming-Shen
MS
Chao
Tsu-Yi
TY
D000970:Antineoplastic Agents / Q000009:adverse effects*; D000998:Antiviral Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006509:Hepatitis B / Q000097:blood / Q000209:etiology / Q000517:prevention & control* / Q000821:virology; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D000998:Antiviral Agents; D006514:Hepatitis B Surface Antigens; D019259:Lamivudine